Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JO9M
|
|||
| Drug Name |
Anti-hCD70 CAR transduced PBL
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [1] | |
| Pancreatic cancer [ICD-11: 2C10] | Phase 1 | [1] | ||
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64] | Phase 1 | [1] | ||
| Company |
National Cancer Institute (NCI)
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CD70 antigen (CD27-L) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| RANKL Signaling Pathway | ||||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.